Citigroup Maintains Buy on Evolent Health, Raises Price Target to $5.5
Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript
Evolent Health, Inc. 2026 Q1 - Results - Earnings Call Presentation
Needham Maintains Buy on Evolent Health, Raises Price Target to $5
Evolent Health Inc - A (NYSE:EVH) Q1 Revenue Miss Overshadowed by EPS Beat
Evolent Health Affirms FY2026 Sales Guidance of $2.400B-$2.600B vs $2.487B Est.
Evolent Health Q1 Adj. EPS $(0.02) Beats $(0.05) Estimate, Sales $496.246M Miss $534.669M Estimate.
Evolent Health (EVH) Price Target Decreased by 32.38% to 6.01
Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $6
Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $4
UBS Maintains Buy on Evolent Health, Lowers Price Target to $5
Evolent Health: Cheap, Levered, But Ready To Rebound
Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $6
Needham Maintains Buy on Evolent Health, Lowers Price Target to $4
Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript
Keybanc Downgrades Evolent Health (EVH)
RBC Capital Maintains Sector Perform on Evolent Health, Lowers Price Target to $3
Evolent Health Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
This First Solar Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Keybanc Downgrades Evolent Health to Sector Weight
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.